Importantly, chemical activators of PP2A can successfully overcome this inhibition and suppress the growth and survival of AML cells signaling through FLT3, suggesting PP2A as a therapeutic target in FLT3+ AML, and adding further weight to the case for clinical trials of PP2A activators in myeloid leukemias. The gene discussed is FLT3; the disease is myeloid leukemia.